Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Below Two Hundred Day Moving Average - Here's Why

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report)'s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $9.11 and traded as low as $6.04. Karyopharm Therapeutics shares last traded at $6.27, with a volume of 94,987 shares.

Analyst Upgrades and Downgrades

KPTI has been the subject of a number of recent analyst reports. Robert W. Baird decreased their target price on Karyopharm Therapeutics from $75.00 to $54.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. HC Wainwright upped their price objective on Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a "buy" rating in a research note on Wednesday, February 26th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $45.00 price target on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $57.50.

Karyopharm Therapeutics Trading Down 3.8%

The company has a 50-day simple moving average of $5.52 and a 200 day simple moving average of $8.94. The firm has a market cap of $49.53 million, a PE ratio of -5.67 and a beta of 0.33.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its earnings results on Wednesday, February 19th. The company reported ($3.60) EPS for the quarter, beating analysts' consensus estimates of ($3.90) by $0.30. The business had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. On average, equities analysts expect that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Velan Capital Investment Management LP acquired a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth about $27,000. Focus Partners Wealth acquired a new position in Karyopharm Therapeutics during the fourth quarter worth approximately $31,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Karyopharm Therapeutics in the fourth quarter valued at approximately $32,000. Two Sigma Advisers LP grew its position in shares of Karyopharm Therapeutics by 145.5% during the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company's stock worth $52,000 after acquiring an additional 45,400 shares during the last quarter. Finally, Opti Capital Management LP acquired a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at $85,000. 66.44% of the stock is owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).